Highly potent broadly neutralizing antibodies offer the best possibility to resolve the current COVID19 pandemic while also preparing for future outbreaks of related viruses.
Our best-in-class broadly neutralizing antibodies can meet the current and future challenges posed by the spillover of coronaviruses into humans.
Our vision is to discover, develop and commercialize antibody-based solutions to address the current COVID-19 pandemic, as well as potential future viral diseases with pandemic potential.
We believe that COVID-19 will become an endemic disease requiring a variety of effective, safe and convenient treatment and preventative options for years to come. We aim to address COVID-19 and future potential coronavirus outbreaks by building a portfolio of antibodies with broadly neutralizing activity against multiple members of the coronavirus family. We are deploying a similar approach to address other respiratory viruses with high pandemic potential.
Our lead product candidate, ADG20, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent.
ADG20 is being evaluated in two, Phase 2/3 clinical trials:
We’re focused on making an impact on global health. Find a position that’s right for you.